PolyPeptide and Numaferm have signed a Preferred Partner Collaboration Agreement for peptide development and production, leveraging PolyPeptide's cGMP manufacturing capacities, regulatory know-how and market access as well as Numaferm's biochemical production platform and expertise in sustainable peptide manufacturing. The parties have agreed to keep the details of the agreement confidential.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.55 CHF | +2.43% | +1.90% | +68.66% |
Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+68.66% | 1.07B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PPGN Stock
- News PolyPeptide Group AG
- PolyPeptide and Numaferm Sign Preferred Partner Collaboration Agreement for Peptide Development and Production